Organisation paid for research Program year 2020 Source: CMS Open Payments

Olympus Management Group

Neither a doctor nor a teaching hospital

Research payments

$43,349

6 payments

Through program year 2020, Olympus Management Group is reported as receiving $43,349 in research payments, across 6 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$4,540	2
2019	Research	$38,809	4

Breakdown

Who paid Research payments · program years 2019–2020

Shire North American Group Inc $38,809 4 payments
Takeda Pharmaceuticals U.S.A., Inc. $4,540 2 payments

Studies the money was for Research payments · program years 2019–2020

A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 Pvp-Iodine 0.6 and Dexamethasone 0.1 Ophthalmic Suspension in the Treatment of Adenoviral Conjunctivitis $34,431 2 payments
A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 Pvp-Iodine 0.6 and Dexamethasone 0.1 Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis $4,378 2 payments
A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 (Pvp-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension in the Treatment of Adenoviral Conjunctivitis $3,865 1 payment
A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 (Pvp-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis $675 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.